2122 related articles for article (PubMed ID: 26230187)
1. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
2. Morphological parameters able to predict BRAF(V600E) -mutated malignancies on thyroid fine-needle aspiration cytology: Our institutional experience.
Rossi ED; Bizzarro T; Martini M; Capodimonti S; Fadda G; Larocca LM; Schmitt F
Cancer Cytopathol; 2014 Dec; 122(12):883-91. PubMed ID: 25156883
[TBL] [Abstract][Full Text] [Related]
3. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
4. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
Chung KW; Yang SK; Lee GK; Kim EY; Kwon S; Lee SH; Park DJ; Lee HS; Cho BY; Lee ES; Kim SW
Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
[TBL] [Abstract][Full Text] [Related]
5. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
[TBL] [Abstract][Full Text] [Related]
6. The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF
Rossi ED; Bizzarro T; Granja S; Martini M; Capodimonti S; Luca E; Fadda G; Lombardi CP; Pontecorvi A; Larocca LM; Baltazar F; Schmitt F
Endocrine; 2017 May; 56(2):379-387. PubMed ID: 27484771
[TBL] [Abstract][Full Text] [Related]
7. Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: a cytohistologic institutional experience.
Rossi ED; Martini M; Capodimonti S; Cenci T; Straccia P; Angrisani B; Ricci C; Lanza P; Lombardi CP; Pontecorvi A; Larocca LM; Fadda G
Cancer Cytopathol; 2014 Jul; 122(7):527-35. PubMed ID: 24639117
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker.
Dell'Aquila M; Granitto A; Martini M; Capodimonti S; Cocomazzi A; Musarra T; Fiorentino V; Pontecorvi A; Lombardi CP; Fadda G; Pantanowitz L; Larocca LM; Rossi ED
Cancer Cytopathol; 2020 Mar; 128(3):177-189. PubMed ID: 31821747
[TBL] [Abstract][Full Text] [Related]
9. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
Kwon HJ; Kim EK; Kwak JY
Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
[TBL] [Abstract][Full Text] [Related]
10. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules.
Kim SK; Kim DL; Han HS; Kim WS; Kim SJ; Moon WJ; Oh SY; Hwang TS
Diagn Mol Pathol; 2008 Jun; 17(2):118-25. PubMed ID: 18382358
[TBL] [Abstract][Full Text] [Related]
11. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.
Zhao H; Zhang ZH; Zhou B; Xiao T; Pan QJ; Guo HQ
Diagn Cytopathol; 2015 Oct; 43(10):786-90. PubMed ID: 26152656
[TBL] [Abstract][Full Text] [Related]
12. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
13. [Expression of BRAF V600E mutation in different thyroid lesions].
Wang W; Li XH; Zhang YH; Li J; Chen J; Zhao P; Li QY; Xiang JJ; Li X; Xu RJ
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):354-7. PubMed ID: 21875464
[TBL] [Abstract][Full Text] [Related]
14. BRAF status of follicular variant of papillary thyroid carcinoma and its relationship to its clinical and cytological features.
Proietti A; Giannini R; Ugolini C; Miccoli M; Fontanini G; Di Coscio G; Romani R; Berti P; Miccoli P; Basolo F
Thyroid; 2010 Nov; 20(11):1263-70. PubMed ID: 20950194
[TBL] [Abstract][Full Text] [Related]
15. Surgical results of thyroid nodules according to a management guideline based on the BRAF(V600E) mutation status.
Kim SK; Hwang TS; Yoo YB; Han HS; Kim DL; Song KH; Lim SD; Kim WS; Paik NS
J Clin Endocrinol Metab; 2011 Mar; 96(3):658-64. PubMed ID: 21239517
[TBL] [Abstract][Full Text] [Related]
16. A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates.
Marchetti I; Lessi F; Mazzanti CM; Bertacca G; Elisei R; Coscio GD; Pinchera A; Bevilacqua G
Thyroid; 2009 Aug; 19(8):837-42. PubMed ID: 19534623
[TBL] [Abstract][Full Text] [Related]
17. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions.
Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH
Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474
[TBL] [Abstract][Full Text] [Related]
18. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
Wobker SE; Kim LT; Hackman TG; Dodd LG
Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
[TBL] [Abstract][Full Text] [Related]
19. Morphological features that can predict BRAF
Rossi ED; Bizzarro T; Martini M; Capodimonti S; Cenci T; Fadda G; Schmitt F; Larocca LM
Cytopathology; 2017 Feb; 28(1):55-64. PubMed ID: 27256275
[TBL] [Abstract][Full Text] [Related]
20. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
Hyeon J; Ahn S; Shin JH; Oh YL
Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
